MSB

3.21%

$1.13 mesoblast limited

Love it,almost feels like you've got an idiot cheat sheet on how...

First 4704 Last

Share
Profile

Follow
finneces

215 Posts.

157

15/09/22

10:46

Post #: 63712128
Share

Originally posted by JB1975: ↑

You wrote (in bold) under a screenshot (which I checked - I watched the whole 58 odd minute August 2020 presentation - and it contained little that was new to me (as I'd previously read the relevant science papers from Levine and Ferrara et al - I've got a manilla folder full of them) and what was new (trials stuff mostly) wasn't relevant to what we are talking about)
"You would also be aware of the only trial completed by that other mob. The only positive data that could be found was in contrast to cohort A cohort B shows a clinical response at day 3 , unfortunately however this is only reported as a clinical response at day 3 so no more accurate biomarker data was given more over long term response is not given. The response may not have been confirmed by the blood test.(tangent)

So don't you think it likely that Remectemcell also delivers a rapid response? detection by far more accurate biomarker data that has also been shown in correlation
to long term survival ?"

First re "You would also be aware of the only trial completed by that other mob"

Maybe I would be aware of it - if you'd bloody well refer to it by something meaningful. Like an announcement or a title or a link. "the only trial completed by that other mob" is to me a pretty much useless reference and you end the paragraph with (tangent) like you yourself know you've gone off somewhere irrelevant but what the heck.

I think one of the things you want to talk about is a study entitled -

Mesenchymal stromal cell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk biomarkers.

Here's the abstract

https://pubmed.ncbi.nlm.nih.gov/34471240/

I've been referring to that in my posts with dachopper as Kasikis et al 2021.

How I work is I often use hardcopies (so I cite the name of the paper or something that can be searched for) and I often get my hardcopies from sci-hub (dot) se.

I can't get into your cohort A and cohort B with something significant on day 3 without some context which you lack of referencing denies me.

What I can offer in reply to your question "So don't you think it likely that Remestemcel also delivers a rapid response? detection by far more accurate biomarker data ... etc etc..." is this.

On page 1 of Kasikis et al 2021 (which you could probably obtain for yourself using sci-hub (dot) se, is this, I think extremely relevant quote

- "The clinical response after 28 days in the remestemcel-L group (18/25, 72%) was higher than in the control group (13/27. 48%), although the difference did not reach statistical significance (p=0.08)."

Now almost nobody else (except you and me - and I've significant doubts about half of us, even though its the half that asked the question) will follow that in my opinion because its too much research into something they aren't interested in, they just want to hear some good news. Most just want to collect evidence to rationalise what they already wish was truth.

But it goes to your question - shouldn't remestemcel-L (assuming it works) show up (as working) pretty quickly. Well at 28 days there wasn't a statistically significant difference in what I consider to be the best data available that MSB has. At 6 months - (180 days) there was a better result for MSB.

Expand

Love it,
almost feels like you've got an idiot cheat sheet on how to debunk
Stupid statement #1 response 1
stupid statement #2 response 2
stupid statement #n response n

MSB Price at posting: 94.0¢ Sentiment: Hold Disclosure: Held
7 Upvote

1 Great analysis

Reply

Top Stories

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

The winners & losers on market if negative gearing were gone

The market's shrugged at China's stimulus measures all year. Why is this one different?

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

There are more pages in this discussion • 6,363 more messages in this thread...

First 4704 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.13		Change 0.035(3.21%)		Mkt cap ! $1.284B

Open	High	Low	Value	Volume
$1.09	$1.13	$1.07	$3.910M	3.535M

Buyers (Bids)

No.	Vol.	Price($)
2	27197	$1.11

Sellers (Offers)

Price($)	Vol.	No.
$1.13	43578	3

View Market Depth

No.	Vol.	Price($)
2	27197	1.105
8	87146	1.100
2	71941	1.095
2	33264	1.090
2	18897	1.085

Price($)	Vol.	No.
1.125	43578	3
1.130	87126	8
1.135	1090	1
1.140	141598	9
1.145	64500	3

Last trade - 16.10pm 27/09/2024 (20 minute delay)

MSB (ASX) Chart

Love it,almost feels like you've got an idiot cheat sheet on how...

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

The winners & losers on market if negative gearing were gone

The market's shrugged at China's stimulus measures all year. Why is this one different?

ACCC seeks Olam divestments before it can buy Namoi Cotton

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Love it,almost feels like you've got an idiot cheat sheet on how...

Top Stories

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

The winners & losers on market if negative gearing were gone

The market's shrugged at China's stimulus measures all year. Why is this one different?

ACCC seeks Olam divestments before it can buy Namoi Cotton

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News